Stereotactic body radiation therapy (SBRT) for centrally located primary and recurrent non-small cell lung cancer (NSCLC): analysis of toxicity and local control
Purpose/objectives Stereotactic body radiation therapy for centrally located lung tumors has been associated with increased risk of toxicity. A current study aims to evaluate tumor control and toxicity in large cohort of centrally located lesions. Methods Central location was defined as tumors withi...
Ausführliche Beschreibung
Autor*in: |
Bowers, John [verfasserIn] Bennion, Nathan R. [verfasserIn] Richardson, Martin [verfasserIn] Spencer, Kelly [verfasserIn] Larner, James [verfasserIn] Kersh, Ronald [verfasserIn] |
---|
Format: |
E-Artikel |
---|---|
Sprache: |
Englisch |
Erschienen: |
2016 |
---|
Schlagwörter: |
---|
Übergeordnetes Werk: |
Enthalten in: Journal of radiation oncology - Berlin : Springer, 2012, 6(2016), 3 vom: 26. Nov., Seite 247-253 |
---|---|
Übergeordnetes Werk: |
volume:6 ; year:2016 ; number:3 ; day:26 ; month:11 ; pages:247-253 |
Links: |
---|
DOI / URN: |
10.1007/s13566-016-0289-9 |
---|
Katalog-ID: |
SPR031812481 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | SPR031812481 | ||
003 | DE-627 | ||
005 | 20230519141841.0 | ||
007 | cr uuu---uuuuu | ||
008 | 201007s2016 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1007/s13566-016-0289-9 |2 doi | |
035 | |a (DE-627)SPR031812481 | ||
035 | |a (SPR)s13566-016-0289-9-e | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
082 | 0 | 4 | |a 610 |q ASE |
100 | 1 | |a Bowers, John |e verfasserin |4 aut | |
245 | 1 | 0 | |a Stereotactic body radiation therapy (SBRT) for centrally located primary and recurrent non-small cell lung cancer (NSCLC): analysis of toxicity and local control |
264 | 1 | |c 2016 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a Purpose/objectives Stereotactic body radiation therapy for centrally located lung tumors has been associated with increased risk of toxicity. A current study aims to evaluate tumor control and toxicity in large cohort of centrally located lesions. Methods Central location was defined as tumors within 2 cm of the bronchial tree, trachea, major vessels, esophagus, heart, pericardium, brachial plexus, or vertebral body. Tumors were biopsy proven or PET positive and included recurrent or primary non-small cell lung cancer (NSCLC). A dose was prescribed to a non-uniform planning target volume based on the internal tumor volume constructed from a 4D CT scan allowing for tumor motion. The treatment plans consisted of non-coplanar static aperture arcs and non-coplanar static fields. Treatments were delivered using 6MV X-rays with image guidance. Results At a median follow-up of 12.3 months, 107 total NSCLC tumors were retrospectively reviewed. A cohort consisted of primary (n = 57) and recurrent (n = 50) NSCLC tumors with subset of recurrent lesions including 27 hilar or mediastinal lymph nodes. Median and most frequent dose were 45 Gy in four fractions treated once weekly. Estimated 2-year Kaplan-Meier survival was 81.7%, with a significant survival advantage between primary and recurrent (p = 0.003). Eleven patients failed locally giving a 2-year actuarial local control rate of 80.7%, with control rates of 82.5 and 79.2% for primary and recurrent tumors, respectively (p = 0.828). Regional control at 2 years was not significantly different for primary (72.6%) and recurrent (62.7%). Analysis of toxicity revealed no grade 4 or 5 events. One grade 3 event was reported as pneumonitis. Grade 2 toxicity occurred in 10 patients, including dyspnea (1), chest wall pain (2), pneumonitis (4), rib fracture (1), and cough (2). Conclusions Moderate prescription dosing, treated once weekly, offers acceptable local control rates for centrally located tumors including recurrent mediastinal and hilar lymph nodes. Toxicity was minimal with the majority of patients experiencing no treatment-related adverse events. | ||
650 | 4 | |a Stereotactic body radiation therapy (SBRT) |7 (dpeaa)DE-He213 | |
650 | 4 | |a Lung |7 (dpeaa)DE-He213 | |
650 | 4 | |a Central |7 (dpeaa)DE-He213 | |
700 | 1 | |a Bennion, Nathan R. |e verfasserin |4 aut | |
700 | 1 | |a Richardson, Martin |e verfasserin |4 aut | |
700 | 1 | |a Spencer, Kelly |e verfasserin |4 aut | |
700 | 1 | |a Larner, James |e verfasserin |4 aut | |
700 | 1 | |a Kersh, Ronald |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Journal of radiation oncology |d Berlin : Springer, 2012 |g 6(2016), 3 vom: 26. Nov., Seite 247-253 |w (DE-627)718611233 |w (DE-600)2660511-9 |x 1948-7908 |7 nnns |
773 | 1 | 8 | |g volume:6 |g year:2016 |g number:3 |g day:26 |g month:11 |g pages:247-253 |
856 | 4 | 0 | |u https://dx.doi.org/10.1007/s13566-016-0289-9 |z lizenzpflichtig |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a SYSFLAG_A | ||
912 | |a GBV_SPRINGER | ||
912 | |a SSG-OLC-PHA | ||
912 | |a GBV_ILN_11 | ||
912 | |a GBV_ILN_20 | ||
912 | |a GBV_ILN_22 | ||
912 | |a GBV_ILN_23 | ||
912 | |a GBV_ILN_24 | ||
912 | |a GBV_ILN_31 | ||
912 | |a GBV_ILN_32 | ||
912 | |a GBV_ILN_39 | ||
912 | |a GBV_ILN_40 | ||
912 | |a GBV_ILN_60 | ||
912 | |a GBV_ILN_62 | ||
912 | |a GBV_ILN_63 | ||
912 | |a GBV_ILN_65 | ||
912 | |a GBV_ILN_69 | ||
912 | |a GBV_ILN_70 | ||
912 | |a GBV_ILN_73 | ||
912 | |a GBV_ILN_74 | ||
912 | |a GBV_ILN_90 | ||
912 | |a GBV_ILN_95 | ||
912 | |a GBV_ILN_100 | ||
912 | |a GBV_ILN_101 | ||
912 | |a GBV_ILN_105 | ||
912 | |a GBV_ILN_110 | ||
912 | |a GBV_ILN_120 | ||
912 | |a GBV_ILN_138 | ||
912 | |a GBV_ILN_150 | ||
912 | |a GBV_ILN_151 | ||
912 | |a GBV_ILN_161 | ||
912 | |a GBV_ILN_170 | ||
912 | |a GBV_ILN_171 | ||
912 | |a GBV_ILN_187 | ||
912 | |a GBV_ILN_213 | ||
912 | |a GBV_ILN_224 | ||
912 | |a GBV_ILN_230 | ||
912 | |a GBV_ILN_250 | ||
912 | |a GBV_ILN_281 | ||
912 | |a GBV_ILN_285 | ||
912 | |a GBV_ILN_293 | ||
912 | |a GBV_ILN_370 | ||
912 | |a GBV_ILN_602 | ||
912 | |a GBV_ILN_636 | ||
912 | |a GBV_ILN_702 | ||
912 | |a GBV_ILN_2001 | ||
912 | |a GBV_ILN_2003 | ||
912 | |a GBV_ILN_2004 | ||
912 | |a GBV_ILN_2005 | ||
912 | |a GBV_ILN_2006 | ||
912 | |a GBV_ILN_2007 | ||
912 | |a GBV_ILN_2008 | ||
912 | |a GBV_ILN_2009 | ||
912 | |a GBV_ILN_2010 | ||
912 | |a GBV_ILN_2011 | ||
912 | |a GBV_ILN_2014 | ||
912 | |a GBV_ILN_2015 | ||
912 | |a GBV_ILN_2020 | ||
912 | |a GBV_ILN_2021 | ||
912 | |a GBV_ILN_2025 | ||
912 | |a GBV_ILN_2026 | ||
912 | |a GBV_ILN_2027 | ||
912 | |a GBV_ILN_2031 | ||
912 | |a GBV_ILN_2034 | ||
912 | |a GBV_ILN_2037 | ||
912 | |a GBV_ILN_2038 | ||
912 | |a GBV_ILN_2039 | ||
912 | |a GBV_ILN_2044 | ||
912 | |a GBV_ILN_2048 | ||
912 | |a GBV_ILN_2049 | ||
912 | |a GBV_ILN_2050 | ||
912 | |a GBV_ILN_2055 | ||
912 | |a GBV_ILN_2057 | ||
912 | |a GBV_ILN_2059 | ||
912 | |a GBV_ILN_2061 | ||
912 | |a GBV_ILN_2064 | ||
912 | |a GBV_ILN_2065 | ||
912 | |a GBV_ILN_2068 | ||
912 | |a GBV_ILN_2070 | ||
912 | |a GBV_ILN_2086 | ||
912 | |a GBV_ILN_2088 | ||
912 | |a GBV_ILN_2093 | ||
912 | |a GBV_ILN_2106 | ||
912 | |a GBV_ILN_2107 | ||
912 | |a GBV_ILN_2108 | ||
912 | |a GBV_ILN_2110 | ||
912 | |a GBV_ILN_2111 | ||
912 | |a GBV_ILN_2112 | ||
912 | |a GBV_ILN_2113 | ||
912 | |a GBV_ILN_2116 | ||
912 | |a GBV_ILN_2118 | ||
912 | |a GBV_ILN_2119 | ||
912 | |a GBV_ILN_2122 | ||
912 | |a GBV_ILN_2129 | ||
912 | |a GBV_ILN_2143 | ||
912 | |a GBV_ILN_2144 | ||
912 | |a GBV_ILN_2147 | ||
912 | |a GBV_ILN_2148 | ||
912 | |a GBV_ILN_2152 | ||
912 | |a GBV_ILN_2153 | ||
912 | |a GBV_ILN_2188 | ||
912 | |a GBV_ILN_2232 | ||
912 | |a GBV_ILN_2336 | ||
912 | |a GBV_ILN_2446 | ||
912 | |a GBV_ILN_2470 | ||
912 | |a GBV_ILN_2472 | ||
912 | |a GBV_ILN_2507 | ||
912 | |a GBV_ILN_2522 | ||
912 | |a GBV_ILN_2548 | ||
912 | |a GBV_ILN_4035 | ||
912 | |a GBV_ILN_4037 | ||
912 | |a GBV_ILN_4046 | ||
912 | |a GBV_ILN_4112 | ||
912 | |a GBV_ILN_4125 | ||
912 | |a GBV_ILN_4242 | ||
912 | |a GBV_ILN_4246 | ||
912 | |a GBV_ILN_4249 | ||
912 | |a GBV_ILN_4251 | ||
912 | |a GBV_ILN_4305 | ||
912 | |a GBV_ILN_4306 | ||
912 | |a GBV_ILN_4307 | ||
912 | |a GBV_ILN_4313 | ||
912 | |a GBV_ILN_4322 | ||
912 | |a GBV_ILN_4323 | ||
912 | |a GBV_ILN_4324 | ||
912 | |a GBV_ILN_4325 | ||
912 | |a GBV_ILN_4326 | ||
912 | |a GBV_ILN_4333 | ||
912 | |a GBV_ILN_4334 | ||
912 | |a GBV_ILN_4335 | ||
912 | |a GBV_ILN_4336 | ||
912 | |a GBV_ILN_4338 | ||
912 | |a GBV_ILN_4393 | ||
912 | |a GBV_ILN_4700 | ||
951 | |a AR | ||
952 | |d 6 |j 2016 |e 3 |b 26 |c 11 |h 247-253 |
author_variant |
j b jb n r b nr nrb m r mr k s ks j l jl r k rk |
---|---|
matchkey_str |
article:19487908:2016----::troatcoyaitoteaybtocnrlyoaepiaynrcretosalelugacrs |
hierarchy_sort_str |
2016 |
publishDate |
2016 |
allfields |
10.1007/s13566-016-0289-9 doi (DE-627)SPR031812481 (SPR)s13566-016-0289-9-e DE-627 ger DE-627 rakwb eng 610 ASE Bowers, John verfasserin aut Stereotactic body radiation therapy (SBRT) for centrally located primary and recurrent non-small cell lung cancer (NSCLC): analysis of toxicity and local control 2016 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Purpose/objectives Stereotactic body radiation therapy for centrally located lung tumors has been associated with increased risk of toxicity. A current study aims to evaluate tumor control and toxicity in large cohort of centrally located lesions. Methods Central location was defined as tumors within 2 cm of the bronchial tree, trachea, major vessels, esophagus, heart, pericardium, brachial plexus, or vertebral body. Tumors were biopsy proven or PET positive and included recurrent or primary non-small cell lung cancer (NSCLC). A dose was prescribed to a non-uniform planning target volume based on the internal tumor volume constructed from a 4D CT scan allowing for tumor motion. The treatment plans consisted of non-coplanar static aperture arcs and non-coplanar static fields. Treatments were delivered using 6MV X-rays with image guidance. Results At a median follow-up of 12.3 months, 107 total NSCLC tumors were retrospectively reviewed. A cohort consisted of primary (n = 57) and recurrent (n = 50) NSCLC tumors with subset of recurrent lesions including 27 hilar or mediastinal lymph nodes. Median and most frequent dose were 45 Gy in four fractions treated once weekly. Estimated 2-year Kaplan-Meier survival was 81.7%, with a significant survival advantage between primary and recurrent (p = 0.003). Eleven patients failed locally giving a 2-year actuarial local control rate of 80.7%, with control rates of 82.5 and 79.2% for primary and recurrent tumors, respectively (p = 0.828). Regional control at 2 years was not significantly different for primary (72.6%) and recurrent (62.7%). Analysis of toxicity revealed no grade 4 or 5 events. One grade 3 event was reported as pneumonitis. Grade 2 toxicity occurred in 10 patients, including dyspnea (1), chest wall pain (2), pneumonitis (4), rib fracture (1), and cough (2). Conclusions Moderate prescription dosing, treated once weekly, offers acceptable local control rates for centrally located tumors including recurrent mediastinal and hilar lymph nodes. Toxicity was minimal with the majority of patients experiencing no treatment-related adverse events. Stereotactic body radiation therapy (SBRT) (dpeaa)DE-He213 Lung (dpeaa)DE-He213 Central (dpeaa)DE-He213 Bennion, Nathan R. verfasserin aut Richardson, Martin verfasserin aut Spencer, Kelly verfasserin aut Larner, James verfasserin aut Kersh, Ronald verfasserin aut Enthalten in Journal of radiation oncology Berlin : Springer, 2012 6(2016), 3 vom: 26. Nov., Seite 247-253 (DE-627)718611233 (DE-600)2660511-9 1948-7908 nnns volume:6 year:2016 number:3 day:26 month:11 pages:247-253 https://dx.doi.org/10.1007/s13566-016-0289-9 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_138 GBV_ILN_150 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_187 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_636 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2070 GBV_ILN_2086 GBV_ILN_2088 GBV_ILN_2093 GBV_ILN_2106 GBV_ILN_2107 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2116 GBV_ILN_2118 GBV_ILN_2119 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2446 GBV_ILN_2470 GBV_ILN_2472 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2548 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4393 GBV_ILN_4700 AR 6 2016 3 26 11 247-253 |
spelling |
10.1007/s13566-016-0289-9 doi (DE-627)SPR031812481 (SPR)s13566-016-0289-9-e DE-627 ger DE-627 rakwb eng 610 ASE Bowers, John verfasserin aut Stereotactic body radiation therapy (SBRT) for centrally located primary and recurrent non-small cell lung cancer (NSCLC): analysis of toxicity and local control 2016 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Purpose/objectives Stereotactic body radiation therapy for centrally located lung tumors has been associated with increased risk of toxicity. A current study aims to evaluate tumor control and toxicity in large cohort of centrally located lesions. Methods Central location was defined as tumors within 2 cm of the bronchial tree, trachea, major vessels, esophagus, heart, pericardium, brachial plexus, or vertebral body. Tumors were biopsy proven or PET positive and included recurrent or primary non-small cell lung cancer (NSCLC). A dose was prescribed to a non-uniform planning target volume based on the internal tumor volume constructed from a 4D CT scan allowing for tumor motion. The treatment plans consisted of non-coplanar static aperture arcs and non-coplanar static fields. Treatments were delivered using 6MV X-rays with image guidance. Results At a median follow-up of 12.3 months, 107 total NSCLC tumors were retrospectively reviewed. A cohort consisted of primary (n = 57) and recurrent (n = 50) NSCLC tumors with subset of recurrent lesions including 27 hilar or mediastinal lymph nodes. Median and most frequent dose were 45 Gy in four fractions treated once weekly. Estimated 2-year Kaplan-Meier survival was 81.7%, with a significant survival advantage between primary and recurrent (p = 0.003). Eleven patients failed locally giving a 2-year actuarial local control rate of 80.7%, with control rates of 82.5 and 79.2% for primary and recurrent tumors, respectively (p = 0.828). Regional control at 2 years was not significantly different for primary (72.6%) and recurrent (62.7%). Analysis of toxicity revealed no grade 4 or 5 events. One grade 3 event was reported as pneumonitis. Grade 2 toxicity occurred in 10 patients, including dyspnea (1), chest wall pain (2), pneumonitis (4), rib fracture (1), and cough (2). Conclusions Moderate prescription dosing, treated once weekly, offers acceptable local control rates for centrally located tumors including recurrent mediastinal and hilar lymph nodes. Toxicity was minimal with the majority of patients experiencing no treatment-related adverse events. Stereotactic body radiation therapy (SBRT) (dpeaa)DE-He213 Lung (dpeaa)DE-He213 Central (dpeaa)DE-He213 Bennion, Nathan R. verfasserin aut Richardson, Martin verfasserin aut Spencer, Kelly verfasserin aut Larner, James verfasserin aut Kersh, Ronald verfasserin aut Enthalten in Journal of radiation oncology Berlin : Springer, 2012 6(2016), 3 vom: 26. Nov., Seite 247-253 (DE-627)718611233 (DE-600)2660511-9 1948-7908 nnns volume:6 year:2016 number:3 day:26 month:11 pages:247-253 https://dx.doi.org/10.1007/s13566-016-0289-9 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_138 GBV_ILN_150 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_187 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_636 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2070 GBV_ILN_2086 GBV_ILN_2088 GBV_ILN_2093 GBV_ILN_2106 GBV_ILN_2107 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2116 GBV_ILN_2118 GBV_ILN_2119 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2446 GBV_ILN_2470 GBV_ILN_2472 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2548 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4393 GBV_ILN_4700 AR 6 2016 3 26 11 247-253 |
allfields_unstemmed |
10.1007/s13566-016-0289-9 doi (DE-627)SPR031812481 (SPR)s13566-016-0289-9-e DE-627 ger DE-627 rakwb eng 610 ASE Bowers, John verfasserin aut Stereotactic body radiation therapy (SBRT) for centrally located primary and recurrent non-small cell lung cancer (NSCLC): analysis of toxicity and local control 2016 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Purpose/objectives Stereotactic body radiation therapy for centrally located lung tumors has been associated with increased risk of toxicity. A current study aims to evaluate tumor control and toxicity in large cohort of centrally located lesions. Methods Central location was defined as tumors within 2 cm of the bronchial tree, trachea, major vessels, esophagus, heart, pericardium, brachial plexus, or vertebral body. Tumors were biopsy proven or PET positive and included recurrent or primary non-small cell lung cancer (NSCLC). A dose was prescribed to a non-uniform planning target volume based on the internal tumor volume constructed from a 4D CT scan allowing for tumor motion. The treatment plans consisted of non-coplanar static aperture arcs and non-coplanar static fields. Treatments were delivered using 6MV X-rays with image guidance. Results At a median follow-up of 12.3 months, 107 total NSCLC tumors were retrospectively reviewed. A cohort consisted of primary (n = 57) and recurrent (n = 50) NSCLC tumors with subset of recurrent lesions including 27 hilar or mediastinal lymph nodes. Median and most frequent dose were 45 Gy in four fractions treated once weekly. Estimated 2-year Kaplan-Meier survival was 81.7%, with a significant survival advantage between primary and recurrent (p = 0.003). Eleven patients failed locally giving a 2-year actuarial local control rate of 80.7%, with control rates of 82.5 and 79.2% for primary and recurrent tumors, respectively (p = 0.828). Regional control at 2 years was not significantly different for primary (72.6%) and recurrent (62.7%). Analysis of toxicity revealed no grade 4 or 5 events. One grade 3 event was reported as pneumonitis. Grade 2 toxicity occurred in 10 patients, including dyspnea (1), chest wall pain (2), pneumonitis (4), rib fracture (1), and cough (2). Conclusions Moderate prescription dosing, treated once weekly, offers acceptable local control rates for centrally located tumors including recurrent mediastinal and hilar lymph nodes. Toxicity was minimal with the majority of patients experiencing no treatment-related adverse events. Stereotactic body radiation therapy (SBRT) (dpeaa)DE-He213 Lung (dpeaa)DE-He213 Central (dpeaa)DE-He213 Bennion, Nathan R. verfasserin aut Richardson, Martin verfasserin aut Spencer, Kelly verfasserin aut Larner, James verfasserin aut Kersh, Ronald verfasserin aut Enthalten in Journal of radiation oncology Berlin : Springer, 2012 6(2016), 3 vom: 26. Nov., Seite 247-253 (DE-627)718611233 (DE-600)2660511-9 1948-7908 nnns volume:6 year:2016 number:3 day:26 month:11 pages:247-253 https://dx.doi.org/10.1007/s13566-016-0289-9 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_138 GBV_ILN_150 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_187 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_636 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2070 GBV_ILN_2086 GBV_ILN_2088 GBV_ILN_2093 GBV_ILN_2106 GBV_ILN_2107 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2116 GBV_ILN_2118 GBV_ILN_2119 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2446 GBV_ILN_2470 GBV_ILN_2472 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2548 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4393 GBV_ILN_4700 AR 6 2016 3 26 11 247-253 |
allfieldsGer |
10.1007/s13566-016-0289-9 doi (DE-627)SPR031812481 (SPR)s13566-016-0289-9-e DE-627 ger DE-627 rakwb eng 610 ASE Bowers, John verfasserin aut Stereotactic body radiation therapy (SBRT) for centrally located primary and recurrent non-small cell lung cancer (NSCLC): analysis of toxicity and local control 2016 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Purpose/objectives Stereotactic body radiation therapy for centrally located lung tumors has been associated with increased risk of toxicity. A current study aims to evaluate tumor control and toxicity in large cohort of centrally located lesions. Methods Central location was defined as tumors within 2 cm of the bronchial tree, trachea, major vessels, esophagus, heart, pericardium, brachial plexus, or vertebral body. Tumors were biopsy proven or PET positive and included recurrent or primary non-small cell lung cancer (NSCLC). A dose was prescribed to a non-uniform planning target volume based on the internal tumor volume constructed from a 4D CT scan allowing for tumor motion. The treatment plans consisted of non-coplanar static aperture arcs and non-coplanar static fields. Treatments were delivered using 6MV X-rays with image guidance. Results At a median follow-up of 12.3 months, 107 total NSCLC tumors were retrospectively reviewed. A cohort consisted of primary (n = 57) and recurrent (n = 50) NSCLC tumors with subset of recurrent lesions including 27 hilar or mediastinal lymph nodes. Median and most frequent dose were 45 Gy in four fractions treated once weekly. Estimated 2-year Kaplan-Meier survival was 81.7%, with a significant survival advantage between primary and recurrent (p = 0.003). Eleven patients failed locally giving a 2-year actuarial local control rate of 80.7%, with control rates of 82.5 and 79.2% for primary and recurrent tumors, respectively (p = 0.828). Regional control at 2 years was not significantly different for primary (72.6%) and recurrent (62.7%). Analysis of toxicity revealed no grade 4 or 5 events. One grade 3 event was reported as pneumonitis. Grade 2 toxicity occurred in 10 patients, including dyspnea (1), chest wall pain (2), pneumonitis (4), rib fracture (1), and cough (2). Conclusions Moderate prescription dosing, treated once weekly, offers acceptable local control rates for centrally located tumors including recurrent mediastinal and hilar lymph nodes. Toxicity was minimal with the majority of patients experiencing no treatment-related adverse events. Stereotactic body radiation therapy (SBRT) (dpeaa)DE-He213 Lung (dpeaa)DE-He213 Central (dpeaa)DE-He213 Bennion, Nathan R. verfasserin aut Richardson, Martin verfasserin aut Spencer, Kelly verfasserin aut Larner, James verfasserin aut Kersh, Ronald verfasserin aut Enthalten in Journal of radiation oncology Berlin : Springer, 2012 6(2016), 3 vom: 26. Nov., Seite 247-253 (DE-627)718611233 (DE-600)2660511-9 1948-7908 nnns volume:6 year:2016 number:3 day:26 month:11 pages:247-253 https://dx.doi.org/10.1007/s13566-016-0289-9 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_138 GBV_ILN_150 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_187 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_636 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2070 GBV_ILN_2086 GBV_ILN_2088 GBV_ILN_2093 GBV_ILN_2106 GBV_ILN_2107 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2116 GBV_ILN_2118 GBV_ILN_2119 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2446 GBV_ILN_2470 GBV_ILN_2472 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2548 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4393 GBV_ILN_4700 AR 6 2016 3 26 11 247-253 |
allfieldsSound |
10.1007/s13566-016-0289-9 doi (DE-627)SPR031812481 (SPR)s13566-016-0289-9-e DE-627 ger DE-627 rakwb eng 610 ASE Bowers, John verfasserin aut Stereotactic body radiation therapy (SBRT) for centrally located primary and recurrent non-small cell lung cancer (NSCLC): analysis of toxicity and local control 2016 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Purpose/objectives Stereotactic body radiation therapy for centrally located lung tumors has been associated with increased risk of toxicity. A current study aims to evaluate tumor control and toxicity in large cohort of centrally located lesions. Methods Central location was defined as tumors within 2 cm of the bronchial tree, trachea, major vessels, esophagus, heart, pericardium, brachial plexus, or vertebral body. Tumors were biopsy proven or PET positive and included recurrent or primary non-small cell lung cancer (NSCLC). A dose was prescribed to a non-uniform planning target volume based on the internal tumor volume constructed from a 4D CT scan allowing for tumor motion. The treatment plans consisted of non-coplanar static aperture arcs and non-coplanar static fields. Treatments were delivered using 6MV X-rays with image guidance. Results At a median follow-up of 12.3 months, 107 total NSCLC tumors were retrospectively reviewed. A cohort consisted of primary (n = 57) and recurrent (n = 50) NSCLC tumors with subset of recurrent lesions including 27 hilar or mediastinal lymph nodes. Median and most frequent dose were 45 Gy in four fractions treated once weekly. Estimated 2-year Kaplan-Meier survival was 81.7%, with a significant survival advantage between primary and recurrent (p = 0.003). Eleven patients failed locally giving a 2-year actuarial local control rate of 80.7%, with control rates of 82.5 and 79.2% for primary and recurrent tumors, respectively (p = 0.828). Regional control at 2 years was not significantly different for primary (72.6%) and recurrent (62.7%). Analysis of toxicity revealed no grade 4 or 5 events. One grade 3 event was reported as pneumonitis. Grade 2 toxicity occurred in 10 patients, including dyspnea (1), chest wall pain (2), pneumonitis (4), rib fracture (1), and cough (2). Conclusions Moderate prescription dosing, treated once weekly, offers acceptable local control rates for centrally located tumors including recurrent mediastinal and hilar lymph nodes. Toxicity was minimal with the majority of patients experiencing no treatment-related adverse events. Stereotactic body radiation therapy (SBRT) (dpeaa)DE-He213 Lung (dpeaa)DE-He213 Central (dpeaa)DE-He213 Bennion, Nathan R. verfasserin aut Richardson, Martin verfasserin aut Spencer, Kelly verfasserin aut Larner, James verfasserin aut Kersh, Ronald verfasserin aut Enthalten in Journal of radiation oncology Berlin : Springer, 2012 6(2016), 3 vom: 26. Nov., Seite 247-253 (DE-627)718611233 (DE-600)2660511-9 1948-7908 nnns volume:6 year:2016 number:3 day:26 month:11 pages:247-253 https://dx.doi.org/10.1007/s13566-016-0289-9 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_138 GBV_ILN_150 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_187 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_636 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2070 GBV_ILN_2086 GBV_ILN_2088 GBV_ILN_2093 GBV_ILN_2106 GBV_ILN_2107 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2116 GBV_ILN_2118 GBV_ILN_2119 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2446 GBV_ILN_2470 GBV_ILN_2472 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2548 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4393 GBV_ILN_4700 AR 6 2016 3 26 11 247-253 |
language |
English |
source |
Enthalten in Journal of radiation oncology 6(2016), 3 vom: 26. Nov., Seite 247-253 volume:6 year:2016 number:3 day:26 month:11 pages:247-253 |
sourceStr |
Enthalten in Journal of radiation oncology 6(2016), 3 vom: 26. Nov., Seite 247-253 volume:6 year:2016 number:3 day:26 month:11 pages:247-253 |
format_phy_str_mv |
Article |
institution |
findex.gbv.de |
topic_facet |
Stereotactic body radiation therapy (SBRT) Lung Central |
dewey-raw |
610 |
isfreeaccess_bool |
false |
container_title |
Journal of radiation oncology |
authorswithroles_txt_mv |
Bowers, John @@aut@@ Bennion, Nathan R. @@aut@@ Richardson, Martin @@aut@@ Spencer, Kelly @@aut@@ Larner, James @@aut@@ Kersh, Ronald @@aut@@ |
publishDateDaySort_date |
2016-11-26T00:00:00Z |
hierarchy_top_id |
718611233 |
dewey-sort |
3610 |
id |
SPR031812481 |
language_de |
englisch |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR031812481</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519141841.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s2016 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s13566-016-0289-9</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR031812481</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s13566-016-0289-9-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Bowers, John</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Stereotactic body radiation therapy (SBRT) for centrally located primary and recurrent non-small cell lung cancer (NSCLC): analysis of toxicity and local control</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2016</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Purpose/objectives Stereotactic body radiation therapy for centrally located lung tumors has been associated with increased risk of toxicity. A current study aims to evaluate tumor control and toxicity in large cohort of centrally located lesions. Methods Central location was defined as tumors within 2 cm of the bronchial tree, trachea, major vessels, esophagus, heart, pericardium, brachial plexus, or vertebral body. Tumors were biopsy proven or PET positive and included recurrent or primary non-small cell lung cancer (NSCLC). A dose was prescribed to a non-uniform planning target volume based on the internal tumor volume constructed from a 4D CT scan allowing for tumor motion. The treatment plans consisted of non-coplanar static aperture arcs and non-coplanar static fields. Treatments were delivered using 6MV X-rays with image guidance. Results At a median follow-up of 12.3 months, 107 total NSCLC tumors were retrospectively reviewed. A cohort consisted of primary (n = 57) and recurrent (n = 50) NSCLC tumors with subset of recurrent lesions including 27 hilar or mediastinal lymph nodes. Median and most frequent dose were 45 Gy in four fractions treated once weekly. Estimated 2-year Kaplan-Meier survival was 81.7%, with a significant survival advantage between primary and recurrent (p = 0.003). Eleven patients failed locally giving a 2-year actuarial local control rate of 80.7%, with control rates of 82.5 and 79.2% for primary and recurrent tumors, respectively (p = 0.828). Regional control at 2 years was not significantly different for primary (72.6%) and recurrent (62.7%). Analysis of toxicity revealed no grade 4 or 5 events. One grade 3 event was reported as pneumonitis. Grade 2 toxicity occurred in 10 patients, including dyspnea (1), chest wall pain (2), pneumonitis (4), rib fracture (1), and cough (2). Conclusions Moderate prescription dosing, treated once weekly, offers acceptable local control rates for centrally located tumors including recurrent mediastinal and hilar lymph nodes. Toxicity was minimal with the majority of patients experiencing no treatment-related adverse events.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Stereotactic body radiation therapy (SBRT)</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Lung</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Central</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bennion, Nathan R.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Richardson, Martin</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Spencer, Kelly</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Larner, James</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kersh, Ronald</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Journal of radiation oncology</subfield><subfield code="d">Berlin : Springer, 2012</subfield><subfield code="g">6(2016), 3 vom: 26. Nov., Seite 247-253</subfield><subfield code="w">(DE-627)718611233</subfield><subfield code="w">(DE-600)2660511-9</subfield><subfield code="x">1948-7908</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:6</subfield><subfield code="g">year:2016</subfield><subfield code="g">number:3</subfield><subfield code="g">day:26</subfield><subfield code="g">month:11</subfield><subfield code="g">pages:247-253</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s13566-016-0289-9</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_32</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_90</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_101</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_120</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_138</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_150</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_171</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_187</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_224</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_250</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_281</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_370</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_636</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2001</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2004</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2006</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2007</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2008</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2010</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2015</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2020</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2021</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2025</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2026</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2027</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2031</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2034</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2038</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2039</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2044</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2048</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2049</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2050</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2057</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2059</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2061</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2064</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2065</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2068</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2070</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2086</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2088</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2093</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2106</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2107</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2108</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2113</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2116</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2118</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2119</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2122</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2129</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2143</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2144</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2147</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2148</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2153</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2188</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2232</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2336</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2446</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2470</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2472</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2507</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2522</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2548</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4035</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4046</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4242</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4246</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4251</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4326</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4333</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4334</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4335</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4336</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4393</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">6</subfield><subfield code="j">2016</subfield><subfield code="e">3</subfield><subfield code="b">26</subfield><subfield code="c">11</subfield><subfield code="h">247-253</subfield></datafield></record></collection>
|
author |
Bowers, John |
spellingShingle |
Bowers, John ddc 610 misc Stereotactic body radiation therapy (SBRT) misc Lung misc Central Stereotactic body radiation therapy (SBRT) for centrally located primary and recurrent non-small cell lung cancer (NSCLC): analysis of toxicity and local control |
authorStr |
Bowers, John |
ppnlink_with_tag_str_mv |
@@773@@(DE-627)718611233 |
format |
electronic Article |
dewey-ones |
610 - Medicine & health |
delete_txt_mv |
keep |
author_role |
aut aut aut aut aut aut |
collection |
springer |
remote_str |
true |
illustrated |
Not Illustrated |
issn |
1948-7908 |
topic_title |
610 ASE Stereotactic body radiation therapy (SBRT) for centrally located primary and recurrent non-small cell lung cancer (NSCLC): analysis of toxicity and local control Stereotactic body radiation therapy (SBRT) (dpeaa)DE-He213 Lung (dpeaa)DE-He213 Central (dpeaa)DE-He213 |
topic |
ddc 610 misc Stereotactic body radiation therapy (SBRT) misc Lung misc Central |
topic_unstemmed |
ddc 610 misc Stereotactic body radiation therapy (SBRT) misc Lung misc Central |
topic_browse |
ddc 610 misc Stereotactic body radiation therapy (SBRT) misc Lung misc Central |
format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
format_main_str_mv |
Text Zeitschrift/Artikel |
carriertype_str_mv |
cr |
hierarchy_parent_title |
Journal of radiation oncology |
hierarchy_parent_id |
718611233 |
dewey-tens |
610 - Medicine & health |
hierarchy_top_title |
Journal of radiation oncology |
isfreeaccess_txt |
false |
familylinks_str_mv |
(DE-627)718611233 (DE-600)2660511-9 |
title |
Stereotactic body radiation therapy (SBRT) for centrally located primary and recurrent non-small cell lung cancer (NSCLC): analysis of toxicity and local control |
ctrlnum |
(DE-627)SPR031812481 (SPR)s13566-016-0289-9-e |
title_full |
Stereotactic body radiation therapy (SBRT) for centrally located primary and recurrent non-small cell lung cancer (NSCLC): analysis of toxicity and local control |
author_sort |
Bowers, John |
journal |
Journal of radiation oncology |
journalStr |
Journal of radiation oncology |
lang_code |
eng |
isOA_bool |
false |
dewey-hundreds |
600 - Technology |
recordtype |
marc |
publishDateSort |
2016 |
contenttype_str_mv |
txt |
container_start_page |
247 |
author_browse |
Bowers, John Bennion, Nathan R. Richardson, Martin Spencer, Kelly Larner, James Kersh, Ronald |
container_volume |
6 |
class |
610 ASE |
format_se |
Elektronische Aufsätze |
author-letter |
Bowers, John |
doi_str_mv |
10.1007/s13566-016-0289-9 |
dewey-full |
610 |
author2-role |
verfasserin |
title_sort |
stereotactic body radiation therapy (sbrt) for centrally located primary and recurrent non-small cell lung cancer (nsclc): analysis of toxicity and local control |
title_auth |
Stereotactic body radiation therapy (SBRT) for centrally located primary and recurrent non-small cell lung cancer (NSCLC): analysis of toxicity and local control |
abstract |
Purpose/objectives Stereotactic body radiation therapy for centrally located lung tumors has been associated with increased risk of toxicity. A current study aims to evaluate tumor control and toxicity in large cohort of centrally located lesions. Methods Central location was defined as tumors within 2 cm of the bronchial tree, trachea, major vessels, esophagus, heart, pericardium, brachial plexus, or vertebral body. Tumors were biopsy proven or PET positive and included recurrent or primary non-small cell lung cancer (NSCLC). A dose was prescribed to a non-uniform planning target volume based on the internal tumor volume constructed from a 4D CT scan allowing for tumor motion. The treatment plans consisted of non-coplanar static aperture arcs and non-coplanar static fields. Treatments were delivered using 6MV X-rays with image guidance. Results At a median follow-up of 12.3 months, 107 total NSCLC tumors were retrospectively reviewed. A cohort consisted of primary (n = 57) and recurrent (n = 50) NSCLC tumors with subset of recurrent lesions including 27 hilar or mediastinal lymph nodes. Median and most frequent dose were 45 Gy in four fractions treated once weekly. Estimated 2-year Kaplan-Meier survival was 81.7%, with a significant survival advantage between primary and recurrent (p = 0.003). Eleven patients failed locally giving a 2-year actuarial local control rate of 80.7%, with control rates of 82.5 and 79.2% for primary and recurrent tumors, respectively (p = 0.828). Regional control at 2 years was not significantly different for primary (72.6%) and recurrent (62.7%). Analysis of toxicity revealed no grade 4 or 5 events. One grade 3 event was reported as pneumonitis. Grade 2 toxicity occurred in 10 patients, including dyspnea (1), chest wall pain (2), pneumonitis (4), rib fracture (1), and cough (2). Conclusions Moderate prescription dosing, treated once weekly, offers acceptable local control rates for centrally located tumors including recurrent mediastinal and hilar lymph nodes. Toxicity was minimal with the majority of patients experiencing no treatment-related adverse events. |
abstractGer |
Purpose/objectives Stereotactic body radiation therapy for centrally located lung tumors has been associated with increased risk of toxicity. A current study aims to evaluate tumor control and toxicity in large cohort of centrally located lesions. Methods Central location was defined as tumors within 2 cm of the bronchial tree, trachea, major vessels, esophagus, heart, pericardium, brachial plexus, or vertebral body. Tumors were biopsy proven or PET positive and included recurrent or primary non-small cell lung cancer (NSCLC). A dose was prescribed to a non-uniform planning target volume based on the internal tumor volume constructed from a 4D CT scan allowing for tumor motion. The treatment plans consisted of non-coplanar static aperture arcs and non-coplanar static fields. Treatments were delivered using 6MV X-rays with image guidance. Results At a median follow-up of 12.3 months, 107 total NSCLC tumors were retrospectively reviewed. A cohort consisted of primary (n = 57) and recurrent (n = 50) NSCLC tumors with subset of recurrent lesions including 27 hilar or mediastinal lymph nodes. Median and most frequent dose were 45 Gy in four fractions treated once weekly. Estimated 2-year Kaplan-Meier survival was 81.7%, with a significant survival advantage between primary and recurrent (p = 0.003). Eleven patients failed locally giving a 2-year actuarial local control rate of 80.7%, with control rates of 82.5 and 79.2% for primary and recurrent tumors, respectively (p = 0.828). Regional control at 2 years was not significantly different for primary (72.6%) and recurrent (62.7%). Analysis of toxicity revealed no grade 4 or 5 events. One grade 3 event was reported as pneumonitis. Grade 2 toxicity occurred in 10 patients, including dyspnea (1), chest wall pain (2), pneumonitis (4), rib fracture (1), and cough (2). Conclusions Moderate prescription dosing, treated once weekly, offers acceptable local control rates for centrally located tumors including recurrent mediastinal and hilar lymph nodes. Toxicity was minimal with the majority of patients experiencing no treatment-related adverse events. |
abstract_unstemmed |
Purpose/objectives Stereotactic body radiation therapy for centrally located lung tumors has been associated with increased risk of toxicity. A current study aims to evaluate tumor control and toxicity in large cohort of centrally located lesions. Methods Central location was defined as tumors within 2 cm of the bronchial tree, trachea, major vessels, esophagus, heart, pericardium, brachial plexus, or vertebral body. Tumors were biopsy proven or PET positive and included recurrent or primary non-small cell lung cancer (NSCLC). A dose was prescribed to a non-uniform planning target volume based on the internal tumor volume constructed from a 4D CT scan allowing for tumor motion. The treatment plans consisted of non-coplanar static aperture arcs and non-coplanar static fields. Treatments were delivered using 6MV X-rays with image guidance. Results At a median follow-up of 12.3 months, 107 total NSCLC tumors were retrospectively reviewed. A cohort consisted of primary (n = 57) and recurrent (n = 50) NSCLC tumors with subset of recurrent lesions including 27 hilar or mediastinal lymph nodes. Median and most frequent dose were 45 Gy in four fractions treated once weekly. Estimated 2-year Kaplan-Meier survival was 81.7%, with a significant survival advantage between primary and recurrent (p = 0.003). Eleven patients failed locally giving a 2-year actuarial local control rate of 80.7%, with control rates of 82.5 and 79.2% for primary and recurrent tumors, respectively (p = 0.828). Regional control at 2 years was not significantly different for primary (72.6%) and recurrent (62.7%). Analysis of toxicity revealed no grade 4 or 5 events. One grade 3 event was reported as pneumonitis. Grade 2 toxicity occurred in 10 patients, including dyspnea (1), chest wall pain (2), pneumonitis (4), rib fracture (1), and cough (2). Conclusions Moderate prescription dosing, treated once weekly, offers acceptable local control rates for centrally located tumors including recurrent mediastinal and hilar lymph nodes. Toxicity was minimal with the majority of patients experiencing no treatment-related adverse events. |
collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_138 GBV_ILN_150 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_187 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_636 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2070 GBV_ILN_2086 GBV_ILN_2088 GBV_ILN_2093 GBV_ILN_2106 GBV_ILN_2107 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2116 GBV_ILN_2118 GBV_ILN_2119 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2446 GBV_ILN_2470 GBV_ILN_2472 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2548 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4393 GBV_ILN_4700 |
container_issue |
3 |
title_short |
Stereotactic body radiation therapy (SBRT) for centrally located primary and recurrent non-small cell lung cancer (NSCLC): analysis of toxicity and local control |
url |
https://dx.doi.org/10.1007/s13566-016-0289-9 |
remote_bool |
true |
author2 |
Bennion, Nathan R. Richardson, Martin Spencer, Kelly Larner, James Kersh, Ronald |
author2Str |
Bennion, Nathan R. Richardson, Martin Spencer, Kelly Larner, James Kersh, Ronald |
ppnlink |
718611233 |
mediatype_str_mv |
c |
isOA_txt |
false |
hochschulschrift_bool |
false |
doi_str |
10.1007/s13566-016-0289-9 |
up_date |
2024-07-04T01:21:05.202Z |
_version_ |
1803609508628398080 |
fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR031812481</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519141841.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s2016 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s13566-016-0289-9</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR031812481</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s13566-016-0289-9-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Bowers, John</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Stereotactic body radiation therapy (SBRT) for centrally located primary and recurrent non-small cell lung cancer (NSCLC): analysis of toxicity and local control</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2016</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Purpose/objectives Stereotactic body radiation therapy for centrally located lung tumors has been associated with increased risk of toxicity. A current study aims to evaluate tumor control and toxicity in large cohort of centrally located lesions. Methods Central location was defined as tumors within 2 cm of the bronchial tree, trachea, major vessels, esophagus, heart, pericardium, brachial plexus, or vertebral body. Tumors were biopsy proven or PET positive and included recurrent or primary non-small cell lung cancer (NSCLC). A dose was prescribed to a non-uniform planning target volume based on the internal tumor volume constructed from a 4D CT scan allowing for tumor motion. The treatment plans consisted of non-coplanar static aperture arcs and non-coplanar static fields. Treatments were delivered using 6MV X-rays with image guidance. Results At a median follow-up of 12.3 months, 107 total NSCLC tumors were retrospectively reviewed. A cohort consisted of primary (n = 57) and recurrent (n = 50) NSCLC tumors with subset of recurrent lesions including 27 hilar or mediastinal lymph nodes. Median and most frequent dose were 45 Gy in four fractions treated once weekly. Estimated 2-year Kaplan-Meier survival was 81.7%, with a significant survival advantage between primary and recurrent (p = 0.003). Eleven patients failed locally giving a 2-year actuarial local control rate of 80.7%, with control rates of 82.5 and 79.2% for primary and recurrent tumors, respectively (p = 0.828). Regional control at 2 years was not significantly different for primary (72.6%) and recurrent (62.7%). Analysis of toxicity revealed no grade 4 or 5 events. One grade 3 event was reported as pneumonitis. Grade 2 toxicity occurred in 10 patients, including dyspnea (1), chest wall pain (2), pneumonitis (4), rib fracture (1), and cough (2). Conclusions Moderate prescription dosing, treated once weekly, offers acceptable local control rates for centrally located tumors including recurrent mediastinal and hilar lymph nodes. Toxicity was minimal with the majority of patients experiencing no treatment-related adverse events.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Stereotactic body radiation therapy (SBRT)</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Lung</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Central</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bennion, Nathan R.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Richardson, Martin</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Spencer, Kelly</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Larner, James</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kersh, Ronald</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Journal of radiation oncology</subfield><subfield code="d">Berlin : Springer, 2012</subfield><subfield code="g">6(2016), 3 vom: 26. Nov., Seite 247-253</subfield><subfield code="w">(DE-627)718611233</subfield><subfield code="w">(DE-600)2660511-9</subfield><subfield code="x">1948-7908</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:6</subfield><subfield code="g">year:2016</subfield><subfield code="g">number:3</subfield><subfield code="g">day:26</subfield><subfield code="g">month:11</subfield><subfield code="g">pages:247-253</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s13566-016-0289-9</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_32</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_90</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_101</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_120</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_138</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_150</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_171</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_187</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_224</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_250</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_281</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_370</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_636</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2001</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2004</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2006</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2007</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2008</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2010</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2015</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2020</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2021</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2025</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2026</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2027</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2031</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2034</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2038</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2039</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2044</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2048</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2049</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2050</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2057</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2059</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2061</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2064</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2065</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2068</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2070</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2086</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2088</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2093</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2106</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2107</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2108</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2113</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2116</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2118</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2119</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2122</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2129</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2143</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2144</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2147</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2148</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2153</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2188</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2232</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2336</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2446</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2470</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2472</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2507</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2522</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2548</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4035</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4046</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4242</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4246</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4251</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4326</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4333</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4334</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4335</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4336</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4393</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">6</subfield><subfield code="j">2016</subfield><subfield code="e">3</subfield><subfield code="b">26</subfield><subfield code="c">11</subfield><subfield code="h">247-253</subfield></datafield></record></collection>
|
score |
7.3985043 |